Dual IL-4Rα/IL-31 Blocker Demonstrates Early Efficacy in Moderate-to-Severe AD

Bambusa Therapeutics, Inc.’s BBT001 produced statistically significant and clinically meaningful improvements in biologic-naïve patients with moderate-to-severe atopic dermatitis (AD) after just four weeks of treatment, with responses evident as early as Week 1 and continuing to improve over time, according to preliminary data from an ongoing global Phase 1 clinical trial.